Literature DB >> 16937340

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data.

Hege Christensen1, Mark Baker, Geoffrey T Tucker, Amin Rostami-Hodjegan.   

Abstract

Although displacement from plasma protein binding (dPB) is usually of little clinical significance, it should be taken into account when interpreting changes in total plasma concentrations of drugs subject to metabolically based drug-drug interactions (mDDI). The aim of this study was to develop an approach to predict changes in the free fractions (fu) of pairs of drugs that compete for plasma binding, knowing their binding affinity constants, and to consider the implications of associated concentration- and time-dependence of such changes with respect to drug exposure. Experimental fu values of valproic acid and phenytoin in the presence of ibuprofen, diflunisal, or naproxen were predicted successfully (within 0.99- to 1.36-fold) by the model. In addition, the simulation of time-dependent changes in fu of valproic acid following administration of ibuprofen indicated different extents of dPB during 'first-pass' through the liver after oral absorption and on systemic recirculation. To understand the impact of the time-dependent change in fu, a full physiologically based pharmacokinetic model, that accounts for concentration-time profile of displacee and displacer and their mutual effect on each other, is required. The approach developed in this study is a first step towards the development of such a model. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937340     DOI: 10.1002/jps.20733

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Using Human Serum Albumin Binding Affinities as a Proactive Strategy to Affect the Pharmacodynamics and Pharmacokinetics of Preclinical Drug Candidates.

Authors:  Jianwei Fan; Katherine Gilmartin; Steven Octaviano; Francisca Villar; Brianna Remache; John Regan
Journal:  ACS Pharmacol Transl Sci       Date:  2022-08-16

Review 2.  Prime Drug Interplay in Dental Practice.

Authors:  Sumedha Mohan; Vivek Govila; Ashish Saini; Sunil Chandra Verma
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 3.  Pharmacokinetic drug interactions in liver disease: An update.

Authors:  Pietro Palatini; Sara De Martin
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

4.  Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.

Authors:  Gergő Dargó; Dávid Bajusz; Kristóf Simon; Judit Müller; György T Balogh
Journal:  J Med Chem       Date:  2020-02-11       Impact factor: 7.446

5.  Concentration-dependent inhibitory effect of Baicalin on the plasma protein binding and metabolism of chlorzoxazone, a CYP2E1 probe substrate, in rats in vitro and in vivo.

Authors:  Na Gao; Dan Zou; Hai-Ling Qiao
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

6.  Contribution of baicalin on the plasma protein binding displacement and CYP3A activity inhibition to the pharmacokinetic changes of nifedipine in rats in vivo and in vitro.

Authors:  Zhen-Yu Cheng; Xin Tian; Jie Gao; Hong-Meng Li; Lin-Jing Jia; Hai-Ling Qiao
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.